Surya Bhatt, MD, associate professor of medicine at University of Alabama at Birmingham, talks about a new trial in which dupilumab was used in patients with chronic obstructive pulmonary disease (COPD) with frequent exacerbations and type 2 inflammation.
Patients with chronic obstructive pulmonary disease (COPD) who also exhibit type 2 inflammation and exacerbations were sought for a trial using dupilumab, said Surya Bhatt, MD, associate professor of medicine at University of Alabama at Birmingham. The study, “Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was presented recently at the American Thoracic Society (ATS) International Conference.
Transcript
Dupilumab is already approved for other indications—can you summarize how it works and why it is being tested for COPD?
Dupilumab is a humanized monoclonal antibody that targets the [interleukin] IL-4 alpha receptor, which is integral to both IL-4 as well as IL-13, and that way it blocks both IL-4 and IL-13 which are very critical for type 2 inflammation in patients with COPD. It's been increasingly recognized that about 20 to 40% of patients with COPD have type 2 inflammation, and they're more likely to suffer from repeated exacerbations. That is the reason why we're targeting patients with COPD with frequent exacerbations and type 2 inflammation with dupilumab.
Who was the patient population in the BOREAS trial of dupilumab and what type of COPD did they have?
BOREAS targeted patients with COPD with type 2 inflammation, and the main inclusion criterion were patients who were current or former smokers with at least a 10 pack/year smoking history and at high exacerbation risk, which was defined as at least 2 moderate exacerbations or 1 severe exacerbation in the previous year. And, they had to have an eosinophil count of at least 300 cells per microliter in the blood to be eligible.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More